- |||||||||| trebananib (AMG 386) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
P1 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer. (Pubmed Central) - Sep 30, 2024
P1
After development of acquired resistance, biopsy of one patient's KRAS wild-type, ERBB2 amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD1 immunotherapy combinations.
- |||||||||| Darzalex (daratumumab) / J&J
Retrospective data, Journal, HEOR, Real-world evidence, Claims database, Real-world: Real-world treatment trends and triple class exposed status in newly diagnosed multiple myeloma patients in Japan: A retrospective claims database study. (Pubmed Central) - Sep 30, 2024
Data from patients with MM were extracted from a Japanese claims database between 2015 and 2022: this study identified patients with NDMM prescribed daratumumab (D), lenalidomide (R), and/or bortezomib (V) as 1st-line treatment...Of 1,784 patients, non-transplant patients (n = 1,656, median age 75 years [range: 37-94]) received R+dexamethasone (Rd) (24.7%), Vd (23.8%), and RVd (15.6%) and transplant patients (n = 128, median age 61 years [range: 35-73]) received RVd (49.5%), Vd (18.7%), and DVd (8.4%) in 1st line...TCE ratio at each line gradually increased from 1st to 5th line (11.1-69.2% in the non-transplant group and 21.1-100% in the transplant group, respectively). Of 184 TCE patients in the non-transplant group, 89.7% received sequencing treatments including DRd, RVd, and DVd, and 10.3% received D-RVd in 1st line.
- |||||||||| ligufalimab (AK117) / Akesobio
Journal, IO biomarker: A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma. (Pubmed Central) - Sep 30, 2024
In addition, in vivo experiments showed that the anti-CD47 mAb AK117 significantly inhibited the growth of subcutaneous xenograft tumors in SCID mice compared to the control antibody IgG. Our results indicate that targeting CD47 monoclonal antibodies is a potential therapeutic strategy for NKTCL.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal: Calibrating Observational Health Record Data Against a Randomized Trial. (Pubmed Central) - Sep 30, 2024
Chemotherapy in both groups was defined as a combination of pemetrexed and platinum-based (carboplatin or cisplatin) therapy...Differences in patient treatment and data capture between the RCT and EHR populations, confounding by indication, treatment crossover, and accuracy of captured diagnoses may explain these findings. Future feasibility assessments will require data sources to have important oncology-specific measures curated.
- |||||||||| Inlyta (axitinib) / Pfizer
Review, Journal: Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies. (Pubmed Central) - Sep 30, 2024
In addition, hypertension due to VEGFR-TKIs may be associated with salt sensitivity, and possible mechanisms of hypertensive side effects are vasodilator imbalance, decreased capillary density, renal injury, impaired endothelial function due to oxidative stress, decreased lymphatic vascular density, and "off-target effect". A comprehensive understanding of hypertension toxicity due to cancer treatment with VEGFR-TKIs, can enhance clinical practice, thereby improving the prognostic outcomes of VEGFR-TKIs in oncology patients.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal: Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab. (Pubmed Central) - Sep 30, 2024
A comprehensive understanding of hypertension toxicity due to cancer treatment with VEGFR-TKIs, can enhance clinical practice, thereby improving the prognostic outcomes of VEGFR-TKIs in oncology patients. No abstract available
- |||||||||| Retrospective data, Journal: Steven-Johnson Syndrome/Toxic Epidermal Necrolysis is Associated with PD-1/PD-L1 Inhibitors Usage: A Case Series. (Pubmed Central) - Sep 30, 2024
Results We identified 12 SJS/TEN patients who had been treated with PD1/PD-L1 inhibitors: sintilimab had been used in six patients; tislelizumab in two cases; toripalimab, keytruda and cadonilimab each in one case; and an unknown prescription in one case...Conclusion This study unveils a potential, under-recognized cause of SJS/TEN in the cancer patients after analyzing the cases of SJS/TEN in cancer patients with prior exposure to PD-1/PD-L1 inhibitors. This paper also provides clue about the prominent features of SJS/TEN aforesaid, offering insights on the effective management measures for optimizing clinical safety.
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: High Tumor Mutational Burden in Hepatocellular Carcinoma. (Pubmed Central) - Sep 30, 2024
In this instance, the high TMB would point toward a worse prognosis, but further study of high-TMB cases is necessary to support a correlation. Given the prevalence of HCC worldwide, any potential avenues that could help guide clinical decision-making should be explored.
- |||||||||| sunitinib / Generic mfg., sorafenib / Generic mfg.
Preclinical, Journal: Design, synthesis, and high-throughput in vitro anti-cancer evaluation of novel 4-aminopyrazolo[3,4-d]pyrimidine derivatives: potential anti-cancer candidates against UO-31 renal cancer cells. (Pubmed Central) - Sep 30, 2024
From the five-dose study, based on IC50 values, the order of activity of compounds against renal cancer cell lines was found to be 12c > 12f > 12c > 12j > 11 with 12c being the most potent, was better than sunitinib and sorafenib. Having been recognized as initial hits, these substances need additional pharmacological investigation.
- |||||||||| alvocidib (DSP-2033) / Sumitomo Pharma, dinaciclib (MK-7965) / Merck (MSD), Visudyne (verteporfin) / Novartis
Journal, IO biomarker: RNA sequencing identifies lung cancer lineage and facilitates drug repositioning. (Pubmed Central) - Sep 30, 2024
Our results indicated that dinaciclib and alvocidib exhibited similar activity and sensitivity in the neuroendocrine cluster. Also, a lineage factor named KLF5 recognized by inferred transcriptional factors activity could be suppressed by verteporfin.
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Tafinlar (dabrafenib) / Novartis
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Adjuvant Therapy in Acral Melanoma: A Systematic Review. (Pubmed Central) - Sep 30, 2024
Targeted therapy with dabrafenib plus trametinib achieved high 12-month RFS in patients with BRAF-mutated acral melanoma...Additionally, prior treatment with pegylated IFN enhanced RFS in patients receiving adjuvant pembrolizumab...Adjuvant anti-PD-1 therapy shows promise, though it may be less effective than in non-acral melanoma. Further prospective studies are needed to determine the optimal adjuvant treatment for acral melanoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens. (Pubmed Central) - Sep 30, 2024
We analyzed LOY in lung adenocarcinoma (LUAD) using both bulk and single-cell expression data and found evidence suggesting that LOY affects the tumor immune environment by altering cancer/testis antigen expression and consequently facilitating tumor immune evasion. Analyzing immunotherapy data, we show that LOY and changes in expression of particular cancer/testis antigens are associated with response to pembrolizumab treatment and outcome, providing a new and powerful biomarker for predicting immunotherapy response in LUAD tumors in males.
- |||||||||| Review, Journal: Efficacy and Effectiveness Outcomes of Treatments for (Pubmed Central) - Sep 30, 2024
Pirtobrutinib, lisocabtagene maraleucel, and a combination of ibrutinib and venetoclax have shown promising effects. However, the scarcity of treatment options and efficacy data for patients who have failed BTKi and venetoclax underscores a significant unmet medical need.
- |||||||||| Rituxan (rituximab) / Roche
Biomarker, Journal: Clinical features and prognostic factors of AIDS-associated diffuse large B-cell lymphoma (Pubmed Central) - Sep 30, 2024
In summary, males, ECOG physical status score of 2 to 4 points, IPI score of 3 to 5 points, EB viral load?1 000 copies/ml and HIV viral load?200 copies/ml are risk factors affecting progression-free survival and overall survival of AIDS-DLBCL patients. RCHOP regimen combined with EB viral load?1 000 copies/ml is a protective factor affecting progression-free survival and overall survival in AIDS-DLBCL patients.
- |||||||||| picropodophyllin (AXL1717) / Axelar, Evrenzo (roxadustat) / FibroGen
Journal: Hypoxia-induced TIMAP Upregulation in Endothelial Cells and TIMAP-dependent Tumour Angiogenesis. (Pubmed Central) - Sep 30, 2024
In the mouse E0771 breast cancer model in vivo, tumor growth and tumor angiogenesis were markedly attenuated in TIMAP deficient, compared to wild-type littermates. These findings indicate that TIMAP plays a critical pro-angiogenic function during tumor angiogenesis in vivo, likely through hypoxia-driven inhibition of the BMP9 pathway and through elaboration of angiogenic growth factors by tumor cells.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Sensory Neuronopathies: Clinical Presentation, Management, and Outcome. (Pubmed Central) - Sep 30, 2024
Promising results were noted in SS-SNN and I-SNN patients with intensive treatment approach using RTX. Hit hard and early treatment approach is crucial for achieving improvement in sensory neuronopathies.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Uveitis: A snapshot in the MOG antibody spectrum. (Pubmed Central) - Sep 30, 2024
This case, characterized by bilateral optic neuritis associated to anti-MOG antibodies and the concurrent onset of unilateral anterior uveitis, provides further evidence concerning the features of intraocular inflammation in MOGAD. The patient's treatment response, including the use of rituximab due to contraindications to oral steroids, emphasizes the importance of personalized management strategies in MOGAD-associated ocular manifestations.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Otitis Media with ANCA-Associated Vasculitis Following COVID-19 mRNA Vaccination: A Case Report. (Pubmed Central) - Sep 30, 2024
Treatment with steroids and rituximab led to recovery of hearing loss and a reduction in myeloperoxidase-ANCA titre...This report has indicated that ANCA-associated vasculitis can be related to COVID-19 mRNA vaccines. As our knowledge of autoimmune disease developing after COVID-19 vaccination is still in the accumulation phase, it is relevant to amass such case reports and use them for assistance in diagnosis in the future.
- |||||||||| Campath (alemtuzumab) / Sanofi
Observational data, Journal, Monotherapy: Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. (Pubmed Central) - Sep 29, 2024
One patient experienced Epstein?Barr virus-positive diffuse large B-cell lymphoma 15 months after the last dose of alemtuzumab. These results confirm that the efficacy and safety of alemtuzumab monotherapy in Japanese patients are comparable to those previously reported.
- |||||||||| Review, Journal: PD-L1: From Cancer Immunotherapy to Therapeutic Implications in Multiple Disorders. (Pubmed Central) - Sep 29, 2024
Moreover, we consider the potential role of PD-L1 in the development and pathogenesis of diseases other than cancer, explore PD-L1-focused therapeutic approaches for these diseases, and assess their clinical relevance. Through this review, we hope to provide deeper insights into the PD-L1/PD-1 signaling pathway and present a broad perspective on potential therapeutic approaches for cancer and other diseases.
- |||||||||| Rituxan (rituximab) / Roche
Biomarker, Journal, IO biomarker: CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients. (Pubmed Central) - Sep 29, 2024
Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC)...The combined analysis of CD16+ monocytes (>?10%) and CD16+ T cells (<?1.6%) provided a strong model with a Harrell's C index of 0.80 and a very strong power of 0.996 even with our sample size of 46 patients. CD16 assessment in the initial blood analysis is thus a precise marker for early relapse prediction.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Retrospective data, Journal, Metastases: Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma. (Pubmed Central) - Sep 29, 2024
The therapeutic landscape for metastatic urothelial carcinoma (mUC) has evolved significantly due to the development of innovative combination treatments, including enfortumab vedotin-pembrolizumab (EVP)...The meta-analysis showed that cisplatin-gemcitabine plus IO combination and carboplatin-gemcitabine plus IO combination improve progression-free survival compared to platinum-gemcitabine therapy (hazard ratio [HR]?=?0.71, 95% CI: 0.62-0.82; P?<?.0001 and HR?=?0.85, 95% CI: 0.73-0.98; P?<?.03, respectively)...In summary, combining cisplatin-gemcitabine with immunotherapy offers significant overall survival benefits in mUC. The exact mechanisms-whether cisplatin's immunomodulatory effects or patient demographic differences-are yet to be determined, necessitating further research to understand these outcomes better.
- |||||||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Journal, Residual disease: Anti-pentraxin 3 antibodies and residual disease activity in rheumatoid arthritis. (Pubmed Central) - Sep 29, 2024
Elevated anti-PTX3 antibodies in RA indicate residual active disease despite controlled inflammation. They may serve as a biomarker for true active disease, especially in seronegative RA patients who might be undertreated.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
P2 data, Journal, Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial. (Pubmed Central) - Sep 29, 2024
A total of 37 patients experienced treatment-related adverse events, of which 17 (20.7%) patients experienced grade 3 or higher adverse events. Collectively, toripalimab plus concurrent platinum-based chemoradiotherapy showed promising antitumor efficacy with acceptable safety profiles in patients with untreated locally advanced cervical cancer.
- |||||||||| Retrospective data, Journal: Characterizing second line and beyond therapies for primary central nervous system lymphomas. (Pubmed Central) - Sep 29, 2024
High-dose methotrexate (HDMTX)-based regimens are recommended frontline treatment, followed by consolidation with either high-dose chemotherapy, whole brain radiation (WBRT) +/- sequential temozolomide (TMZ), or autologous stem cell transplant (autoSCT)...The second line treatments were WBRT (24%), clinical trial (18%), rituximab with lenalidomide (R2; 18%), re-induction with HDMTX-based regimens (18%), ibrutinib with rituximab (12%) and R-HDAC (12%)...Treatments varied, including R2; ibrutinib +/- HDMTX; rituximab, methotrexate, and cytarabine; R-HDAC; R-nivolumab; and WBRT...Regimens used for the three patients who received fifth line treatment and beyond included R-TMZ and pembrolizumab monotherapy in addition to previously described regimens. Regimen selection is varied and highly dependent on physician preference and patient factors, including
- |||||||||| Review, Journal: Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits. (Pubmed Central) - Sep 29, 2024
Regimen selection is varied and highly dependent on physician preference and patient factors, including Biotechnology progress enables targeted biologic therapies for SLE, reducing disease activity and improving patients' quality of life.
|
